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Wepreviously reported that an envelope (Env) glycoprotein immunogen (o-gp140ΔV2SF162) containing a partial deletion in the second variable
loop (V2) derived from the R5-tropic HIV-1 isolate SF162 partially protected vaccinated rhesus macaques against pathogenic SHIVSF162P4 virus.
Extending our studies to subtype C isolate TV1, we have purified o-gp140ΔV2TV1 (subtype C ΔV2 trimer) to homogeneity, performed
glycosylation analysis, and determined its ability to bind CD4, as well as a panel of well-characterized neutralizing monoclonal antibodies (mAb). In
general, critical epitopes are preserved on the subtype CΔV2 trimer; however, we did not observe significant binding for the b12mAb. Themolecular
mass of subtype C ΔV2 trimer was found to be 450 kDa, and the hydrodynamic radius was found to be 10.87 nm. Our data suggest that subtype C
ΔV2 trimer binds to CD4 with an affinity comparable to o-gp140ΔV2SF162 (subtype BΔV2 trimer). Using isothermal titration calorimetric (ITC)
analysis, we demonstrated that all three CD4 binding sites (CD4-BS) in both subtype C and B trimers are exposed and accessible. However, compared
to subtype B trimer, the three CD4-BS in subtype C trimer have different affinities for CD4, suggesting a cooperativity of CD4 binding in subtype C
trimer but not in subtype B trimer. Negative staining electron microscopy of the subtype C ΔV2 trimer has demonstrated that it is in fact a trimer.
These results highlight the importance of studying subtype C Env, and also of developing appropriate subtype C-specific reagents that may be used
for better immunological characterization of subtype C Env for developing an AIDS vaccine.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV; Trimer; Subtype C; CD4; Neutralizing antibodies; ITCIntroduction
Acquired Immunodeficiency Syndrome (AIDS) continues to
be a major health problem throughout the world, with approxi-
mately 40 million people infected with the human immunode-
ficiency virus type 1(HIV-1) and 20 million deaths due to AIDS
to date. In the United States, an estimated one million individuals
are currently living with HIV, and 40,000 to 80,000 new primary
infections occur each year (UNAIDS/WHO, 2004). The situation
is continuously deteriorating as a result of the rapid emergence of⁎ Corresponding author. Fax: +1 510 923 2586.
E-mail address: indresh.srivastava@novartis.com (I.K. Srivastava).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2007.10.022drug resistance against most of the effective anti-virals. In certain
parts of the world, such as Sub-Saharan Africa, India, and China,
HIV-1 subtype C is the most prevalent strain. For instance, in
Botswana and Swaziland, the prevalence of subtype C HIV
infection is estimated to be as high as 35% (UNAIDS/WHO,
2004). Therefore, there is an urgent need for an effective anti-HIV
vaccine that can be used either alone as a prophylactic vaccine, or
in conjunction with effective anti-virals as a therapeutic vaccine.
In the mid 1980s, during the early phase of the AIDS epi-
demic, induction of neutralizing antibodies (nAbs) was believed
to be sufficient to protect against HIV infection. However,
preclinical and early clinical trials in the early 1990s (Mascola
et al., 1993, 1996) confirmed that the neutralizing antibody
274 I.K. Srivastava et al. / Virology 372 (2008) 273–290responses induced by the monomeric HIV Env vaccines being
tested at that time did not offer the breadth necessary to either
prevent or control infection with naturally acquired field isolates
of HIV. The focus then changed to the development of vaccines
and regimens that would induce strong cellular responses. Early
preclinical studies in rhesus macaques had established the
correlation between strong cytotoxic T-cell (CTL) activity and
reduced viral load. Subsequent studies using DNA prime/vector
boost and vector prime/vector boost further strengthened the
observation that strong cellular responses can serve as correlates
of protection from disease development in animal models.
However, recent data obtained in a rhesus macaque challenge
model suggest that cellular responses that focus on a single
epitope may not be sufficient to effectively control viral repli-
cation for extended periods of time due to the emergence of
escape mutants (Barouch et al., 2003, 2002; Barouch and Letvin,
2002; Vogel et al., 2003). It remains to be seen if increasing the
breadth and potency of vaccine-elicited CTL responses will have
a positive impact on the outcome of challenge infection. It is now
widely believed that humoral, cellular, and T-helper cell re-
sponses, both at peripheral and mucosal sites, are needed to
provide broad and durable protection against HIV. Conceptually,
antibodies would serve as a first line of defense by either
completely preventing infection or reducing the virus inocu-
lums. Cellular responses would then facilitate the clearance of
HIV-infected CD4+ T-cells that have escaped antibody-
mediated neutralization and reduce the severity of the disease.
In a proof of concept study, Mascola et al. (2003) have shown
that the induction of cellular responses using DNA vaccines in
conjunction with passive transfer of nAbs did not exceed the
protection afforded by passive transfer of nAbs alone. Further
studies will be needed to demonstrate any potential advantage of
inducing both potent cellular and humoral responses by an
effective HIV vaccine.
The induction of broadly reactive nAbs against primary HIV-
1 strains may prevent HIV infection by blocking the initial stage
of infection (Graham, 2000). Although it is difficult to elicit
broadly nAbs against primary HIVor SIV strains in humans and
in nonhuman primates (Johnston and Flores, 2001; Parren et al.,
2001), it has been shown that antibodies induced by prime-boost
vaccine regimens can prevent immunodeficiency virus infection
by inducing effective neutralizing antibody responses. For
example, priming chimpanzees with replication-competent
adenovirus-HIV gp160 recombinants, followed by boosting
them with HIV-1 SF2 gp120 in MF59, elicited high serum titers
of antibodies capable of neutralizing homologous and heterol-
ogous primary HIV-1 isolates in vitro. This finding correlated
with in vivo protection of the animals against multiple, intra-
venous viral challenges (Robert-Guroff et al., 1998; Zolla-Pazner
et al., 1998). Furthermore, Mascola et al. (1999) and Ruprecht
et al. (2001) have clearly demonstrated the positive effect of nAbs
in passive immunizations upon the outcome of the challenge
infection. Thus, the induction of broadly neutralizing antibody
responses is important for developing an effective HIV vaccine.
The main question now is how to design immunogens that
can induce nAbs of the right specificity and affinity to provide
meaningful levels of protection against challenge with fieldisolates of HIV. We have pursued a modified-envelope HIV
vaccine approach based on deleting the second hyper variable
region (V2) from HIV envelope immunogens. This approach is
based on several observations: (i) deletion of the V2 loop re-
sulted in 100-fold increased susceptibility of antibody-mediated
neutralization of mutant virus (Stamatatos and Cheng-Mayer,
1998a); (ii) deletion of the V2 loop alters the entry of mutant
virus in CD4+ T-cells (Wyatt et al., 1995); (iii) CD4-inducible
mAbs – such as 17b and 48d – better recognize V1/V2-deleted
envelopes (Sullivan et al., 1998; Wyatt et al., 1995); and (iv)
envelopes without V1 and V2 loops can mediate fusion with
CCR5+ cells in the absence of the CD4 receptor (Johnson et al.,
2002). Taken together, these observations suggest that the V1
and V2 loops may mask conserved regions of the envelope
involved in viral entry and susceptibility to neutralization
(Johnson et al., 2002; Stamatatos and Cheng-Mayer, 1998b;
Sullivan et al., 1998; Wei et al., 2003; Wyatt et al., 1995). In
addition, removal of the V1 and V2 loops may also eliminate
several potential N-linked glycosylation sites (NLGS) and ex-
pose critical functional epitopes as recently described in the
“glycan shield” model proposed by Wei et al. (2003). Ly and
Stamatatos (2000) have demonstrated that elimination of
specific NLGS from the V2 loop renders the virus more sus-
ceptible to neutralization by various mAbs. Therefore, develop-
ment of novel Env immunogens based on V2 loop deletion is
relevant to developing an HIV vaccine. By introducing a partial
deletion of the V2 loop in HIV Env immunogens derived from
the R5-tropic, subtype B HIV strain SF162, we have altered the
immunogenic properties of HIV Env as demonstrated by the
immunogenicity studies in different animal models (Barnett
et al., 2001; Srivastava et al., 2003). Priming rhesus macaques
with ΔV2SF162-envelope-encoding DNA vaccines, followed
by boosting with o-gp140ΔV2SF162, confers partial protection
against a pathogenic SHIVSF162P challenge (Barnett et al.,
2001; Cherpelis et al., 2001a,b). Quinnan et al. (2005) demon-
strated that priming of rhesus macaques with alpha virus
expressing R2 Env, followed by boosting with oligomeric
protein, induced antibodies that neutralized diverse primary
isolates. Furthermore, immunized rhesus macaques were pro-
tected against the challenge with partially pathogenic SHIV
DH12R (Clone 7) as reflected by a reduction in the magnitude
and duration of virus load.
In a more recent study, Quinnan and colleagues have clearly
demonstrated that trimeric Env compared to monomeric Env is
a potent immunogen (Zhang et al., 2007). They have
demonstrated that gp140R2 immunogen induced antibodies
that achieved 50% neutralization of 48/48, and 80% neutrali-
zation of 43/46 primary strains of diverse HIV-1 subtypes
tested. The strains tested included members of standard panels
of subtype B and C strains, and other diverse strains known to
be neutralization resistant. The gp120R2 induced antibodies
neutralized only 9/48 of the same strains. Neutralization was
IgG-mediated and HIV-1-specific.
Previously we reported on the engineering and characteriza-
tion of soluble trimeric gp140 proteins derived from SF162
lacking the V2 loop (Srivastava et al., 2003). Here, we describe
the purification and characterization of V2 loop-deleted Env
Fig. 1. Structure and stabilization of HIV-1 subtype C Env in trimeric
conformation. The linear map of gp120ΔV2 and gp41 of subtype C Env is
presented. The gp120 variable regions (V1 to V5) are indicated as different
shaded squares, and the protease cleavage site is marked with an arrow. All the
protease cleavage site mutations (primary and secondary) that were evaluated for
stabilizing subtype C trimers are shown. Effect of these mutations on the
expression and stabilization of subtype C Env in trimeric conformation is also
presented (T stands for trimer, and M for monomer).
Table 1
Development of stable CHO cell clones secreting o-gp140ΔV2TV1
No. of clones Methotrexate concentration (nM) Expression (ng/ml)
588 50 nd
84 50 200–400
36 100 500–1900
34 200 500–1900
21 400 400–1400
21 800 500–2300
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isolate derived from South Africa. We have previously shown
that TV1 immunogens elicited homologous nAbs, and provided
some breadth against a panel of heterologous subtype B and
subtype C primary isolates (Lian et al., 2005). EM studies in-
dicate that the purified protein is in a stable trimeric confor-
mation; immunochemical studies indicate that the subtype C
ΔV2 trimer binds to CD4 at an affinity similar to subtype BΔV2
trimers, and it has comparable glycosylation profile to subtype B
ΔV2 trimer. However, there are differences between subtype B
and C ΔV2 trimers in the binding profiles of mAbs. Our studies
reveal differences in the presentation of neutralization epitopes
on clade B and clade C gp140 immunogens that could affect the
elicitation of neutralizing antibody responses.
Results and discussion
Results
Selection of subtype C HIV envelope
Several well-characterized subtype C isolates from South
Africa (Estrelita Van Rensburg, Tygerberg Hospital, University
of Stellenbosch) were evaluated for their sensitivity to
neutralization by homologous and heterologous sera. The Env
genes derived from proviral sequences from six clade C infected
patients were amplified using primers derived from subtype C
consensus sequence, and we cloned the PCR product in an
expression vector. The insert was confirmed by restriction
enzyme digest. The Env from six different clones was expressed,
and characterized for level of expression in 293 and RD cells and
its ability to bind to CD4. Only two clones expressed Env in 293
cells to a reasonable level, and the partially purified Env proteins
bound to CD4 in an HPLC-based assay (data not shown). No
detectable expression of any Env clone was observed in RD
cells. Based on expression profile, CD4 binding, and fusogeni-
city (Lian et al., 2005), TV1 was selected for further studies.
Analysis of leader sequences
To optimize the secretion of the expressed Env protein
(gp120), three different leader sequences were evaluated tran-
siently for the level of expression of secreted protein: (i) subtypeC specific native leader sequence (Native), (ii) tissue plasmin-
ogen activator leader sequence (tPA), and (iii) an optimized
version of the tPA sequence (tPAopt). Expressed Env proteins
were partially purified, and analyzed by SDS-PAGE, and immu-
noprobing. The quantity of Env proteins secreted by these con-
structs was relatively similar (data not shown). Therefore, the
construct with native leader sequence was chosen for further
evaluation.
Expression and stabilization of o-gp140ΔV2TV1
Tomaximize the expression of gp140TV1ΔV2, the gene was
modified. Consistent with our previous observations (Srivastava
et al., 2003, 2002; zur Megede et al., 2000), modified constructs
expressed significantly higher levels of Env protein compared to
un-optimized constructs (data not shown). We have previously
shown that introduction of a single mutation (Arginine to Serine)
in the protease cleavage site in HIV-1 Env gene from US4
(a subtype B primary isolate) was effective for stabilization of
trimers (Srivastava et al., 2002). However, the same R-to-S
mutation was relatively ineffective for stabilization of trimers
derived from SF162 (Srivastava et al., 2003), and also for TV1
(Fig. 1). Therefore, we evaluated several different combinations
of mutations in the primary (aa494 to 497; REKR) and
secondary (aa486 to 490; KAKRR) protease cleavage sites for
their relative abilities to stabilize the TV1 Env trimer (Fig. 1).
Based upon expression profile, molecular mass and sCD4
binding, construct #7 which had a total of five mutations [two in
the primary (E495-S, R497-S) and three in the secondary
cleavages site (K488-I, R489-S and R490-S)] was the most
effective at stabilizing the Env trimer. These mutations were
used to derive stable CHO cell lines secreting o-gp140ΔV2TV1.
Selected clones were grown in presence of methotrexate at
concentrations ranging from 50 nM to 800 nM, andmaintained for
a period of 3–4 weeks at one methotrexate concentration before
moving on to the next drug concentration. Expression of Env was
continuously monitored using a capture ELISA (Table 1). Based
on the expression profile at the highest methotrexate concentra-
tion, the three best clones were selected for further evaluation and
adaptation in a 3.5 L perfusion bioreactor. Clone #24Rwas chosen
as the cell line for the production of gp140ΔV2TV1, based on
level of Env expression and growth characteristics of the cells.
Purification of o-gp140ΔV2TV1
A three-step strategy was used for efficient purification of
o-gp140ΔV2TV1, involving a capture and two cleaning steps.
The Env protein was efficiently captured over a GNA lectin
column, while most contaminating proteins flowed through. The
Fig. 2. Purification of subtype C Env protein. SDS-PAGE analysis of subtype C Env captured on GNA column (A: lane 2—starting material, lane 3—flow through after
GNA column, lane 4—pool of GNA elutions, lane 5—GNA elution (concentrated), lane 6—flow through after DEAE; lane 7—10× concentrated DEAE flow-through;
lane 8—CHAP flow through). Analysis of different concentrations of final preparation of subtype C Env trimer (B: lane 1—2 μg, lane 2—5 μg, lane 3—10 μg, and lane
4—molecular weight standard). Final preparation of subtypeCEnv trimer was characterized by immunoprobing using amAb (20-2-C8.5F3) (C: lane 2—gp120SF2 and
lane 3—o-gp140ΔV2TV1), and size exclusion-HPLC profile of the purified subtype C Env proteins (D). Trimers (T) and monomers (M) are indicated.
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(MMP). It was then passed over DEAE and CHAP columns,
where contaminating proteins bound to the columns, but Env
flowed through. The fractions collected from each column were
analyzed by SDS-PAGE, immunoblot, size exclusion column
chromatography (SEC), and a CD4 binding assay (Fig. 2). The
GNA lectin was very efficient at capturing the Env (N90%), but
the purity was less than 50% (Fig. 2A). After the DEAE column,
Env preparation was more than 60–70% pure, and the major
contaminant was a serum protein (α-2 macroglobulin) (Fig. 2A).
However after the final step, i.e. CHAP column, Env was more
than 95% pure (Fig. 2A). The Env preparation was concentrated
using a 100 kDa membrane, buffer was exchanged, and it was
analyzed over SDS-PAGE (Fig. 2B) where purity was estimated
to be N95% by densitometric scanning (data not shown). Further-
more, to determine the proportion of trimer, the purified prep-
aration was analyzed over a BioSil 250 SEC (Fig. 2D). Based on
the SEC profile, the purified Env preparation consisted of ap-
proximately 70–80% oligomer and 20–30%monomer (Fig. 2D).
Therefore, at a final stage of purification, Env trimer was sep-
arated from monomer on a higher resolution, pre-calibrated
Superdex-200 column with molecular weight standards of 670,
158, 44, 17, and 1.35 kDa (Fig. 3A). We pooled different
fractions constituting different parts of the peak to make five
different pools. These pools were analyzed on PAGE under
native (Fig. 3B) and reduced and denaturing conditions (Fig. 3C).
The data suggest that purified Env was in three different confor-
mations: (i) larger structures representing the aggregated species
N670 kDa (pool 1); (ii) trimers N440 kDa (pools 2, 3); and (iii)
dimer b440 kDa (pool 4), and monomer N140 kDa (pool 5).
However, all of these fractions migrated with an apparent
molecular mass of 140 kDa on reducing and denaturing SDS-PAGE (Fig. 3C). No change in the electrophoretic mobility of
these fractions was observed under denaturing conditions com-
pared to reducing and denaturing conditions (data not shown)
suggesting that Env monomers were noncovalently associated
with each other to give rise to trimers. To further confirm that the
purified Env is a genuine trimer, and not a disulfide-linked
aggregate, the purified oligomers were treated with increasing
concentrations of β-ME, and the samples were analyzed by
HPLC using BioSil 250 column. No change in the mass of the
Env protein was observed as reflected by the retention time upon
treatment with increasing β-ME concentration suggesting that
the trimers were not disulfide-linked aggregates (data not
shown). Purified subtype C ΔV2 trimer was recognized as a
single species on westerns blot usingMAb 20-2-C8.5F3 directed
against the conserved (C4) domain of subtype B gp120 (Fig. 2C)
suggesting that there is no major degradation or proteolysis
of o-gp140ΔV2TV1, and that the purified preparation was
homogeneous.
Biochemical characterization of o-gp140ΔV2TV1
Glycosydic linkage analysis. The nature of the oligosacchar-
ides linkages in the purified subtype C ΔV2 trimer was
analyzed by digesting the Env protein with PNGF, which
releases asparagine-linked oligosaccharides, with NANase II
and O-glycosidase DS, which release unsubstituted Gal (β1, 3)
GalNAc (α1) disaccharides attached to serine or threonine,
either alone or in combination. Like o-gp140ΔV2SF162, sub-
type C ΔV2 trimer contained predominantly N-linked oligo-
saccharides since PNGF treatment appeared to remove all the
sugars (Fig. 4A, lanes 3 and 6). Furthermore, we observed that
NANase and O-glycosidase DS had no effect on electrophoretic
Fig. 4. Carbohydrate linkage analysis of purified subtype C Env trimer [A:
o-gp140ΔV2 TV1 digested with PNGF (lane 3), O-glycosidase (lane 4), and
NANase (lane 5)]. o-gp140ΔV2 TV1 was also digested with NANase,
O-glycosidase, and PNGF mixed all together (lane 6). Undigested subtype C
Env trimer was used as a control (lane 2), and molecular weight standards are
included in lane 1. (B) Endo-H digestion of subtype C Env trimer (lane 2).
Molecular weights are indicated in lane 3. The + and − signs indicate if the
digestion was performed with and without Endo-H.
Fig. 3. Fractionation of purified subtype C Env protein on pre-calibrated Superdex-200 size exclusion column to separate trimers from the dimers and/or monomers (A).
Analysis of different pools on polyacrylamide gels both under native conditions (B: lane 2—CHAP flow through, lane 3—pool 1, lane 4—pool 2, lane 5—pool 3, lane 6—
pool 4, lane 7—pool 5; molecular weight standards in lanes 1 and 8); and in reducing and denaturing conditions (C: lanes 3—CHAP flow through, lane 4—pool 1, lane 5—
pool 2, lane 6—pool 3, lane 7—pool 4, lane 8—pool 5; molecular weight standards in lanes 1). Pools 2 and 3 predominantly contain trimeric Env protein are marked.
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respectively), similar to subtype BΔV2 trimer (Srivastava et al.,
2003) and also for o-gp140US4 (Srivastava et al., 2002).
Finally, digestion of subtype CΔV2 trimer with a mixture of all
three enzymes also had no discernible effect on the electropho-
retic mobility compared to digestion with PNGF alone (Fig. 4A,
lane 6). This is similar to what was previously reported by
others and us for HIV Env proteins in monomeric and oligo-
meric conformation (Kozarsky et al., 1989; Srivastava et al.,
2002). Therefore, recombinant subtype C gp140ΔV2 trimers
expressed in CHO cells contained few or no O-linked
oligosaccharides, as was observed for both native (released
from virions) and recombinant gp120 (Geyer et al., 1988;
Mizuochi et al., 1988) and also for recombinant o-gp140 from
US4 (Srivastava et al., 2002). To ensure that purified Env was
secreted from cells after passage through the endoplasmic re-
ticulum and Golgi versus that released from the intracellular
compartments by dead cells, Env was treated with Endo-H,
which releases terminal mannose carbohydrates. After Endo-H
digestion, a 15–20% reduction in the apparent molecular mass
of subtype C ΔV2 trimer was observed (Fig. 4B), suggesting
that not all high mannose sugars are exposed on the surface of
the molecule, and carbohydrate modification of subtype C ΔV2
trimer has taken place in the Golgi network. This is in agree-
ment with earlier data demonstrating that HIV Env protein has
heterogeneous glycosylation.Binding of subtype C ΔV2 trimer to CD4. The ability of
native HIV Env to bind CD4 is essential for its biological
function and can, therefore, serve as an indicator of native
Fig. 5. Binding of purified subtype C (B) and subtype B (A)ΔV2 Env trimers to CD4 as determined by an HPLC-based CD4 binding assay. The kinetic analysis of subtype B and subtype C Env trimers binding to immobilized
sCD4 was performed using SPR technique; binding sensograms (top part) along with residuals (bottom part) are presented in panels C (subtype CΔV2 trimer) and D (subtype BΔV2 trimer). Different sensograms in panels C
and D were generated using a range of trimeric Env concentrations (37 to 250 nM). These data were prepared for kinetic analysis by subtracting binding responses collected from a blank reference surface. The association and
dissociation phase data were fitted simultaneously to a single-site binding model by using Biaevaluation 3.2. The summary of the kinetic data for both subtype B and C ΔV2 trimers is presented in panel E.
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(Scandella et al., 1993). Using an HPLC-based receptor-binding
assay (Srivastava et al., 2002), subtype C ΔV2 Env was shown
to bind to CD4 (Fig. 5B) similar to theΔV2 trimer derived from
SF162 (Fig. 5A). However, the retention time for subtype C
ΔV2 trimer was shorter compared to subtype B ΔV2 trimer,
suggesting that subtype C ΔV2 trimer is larger compared to
subtype B ΔV2 trimer. The kinetic constants observed for ΔV2
trimers derived from TV1 and SF162 are presented in Figs. 5C–
E. The calculated on rates forΔV2TV1 andΔV2SF162 trimers
were 1.09E+04 and 7.43E+03, respectively. In addition, the
dissociation rate for subtype C ΔV2 trimer was slightly slower
compared to subtype B ΔV2 trimer. These data suggest tat
ΔV2TV1 trimer has higher binding affinity to sCD4 than
ΔV2SF162 trimer.
Isothermal titration calorimetric analysis. Since isothermal
titration calorimetric (ITC) analysis is a very powerful tech-
nique not only for the strength of interaction, but also for
determining the stoichiometry of receptor ligand binding, ITC
was used to determine the stoichiometry of Env trimer and CD4.
The data are presented in Fig. 6. For the data analysis, it wasFig. 6. Thermodynamic properties of subtype C ΔV2 trimer were determined using is
and the heat of mixing and dilution was subtracted from the final data. Panel A represe
each injection (power: time). The area under each spike is proportional to the heat con
mole of injected ligand (envelope) as a function of molar ratio. For the trimeric Envs,
The solid line represents the best nonlinear fit to the experimental data. The kinetic dat
active sites in Env for CD4 (N) are presented in panel C. In panel D, the kinetic daassumed that if all the CD4 binding sites in the trimer were
accessible, then the number of active sites (N) would be equal to
3, whereas for monomer the N would be equal to 1. The calcu-
lated numbers of CD4 binding sites for the trimer were found to
be 2.79 and 0.965 for the trimer and monomer, respectively
(Fig. 6C), suggesting that N90% of the Env molecules were
functionally active in terms of their ability to bind CD4, and all
three CD4 binding sites in the purified subtype C trimers are
accessible. We have also calculated the affinity of each binding
site in Env trimer for CD4. It was quite interesting to note that
all three CD4 binding sites in the subtype C ΔV2 trimer had
different KDs, suggesting cooperativity in binding (Fig. 6D).
This is in contrast to subtype BΔV2 trimer, where all three CD4
binding sites had relatively similar KDs (Sharma et al., 2006).
Immunochemical characterization of o-gp140ΔV2TV1
The structural integrity of subtype C Env was further eval-
uated by surface immunoprobing with a panel of mAbs of
defined epitope specificities (IgGCD4, b12, 2F5, 4E10, 447D,
391-95d, G34, 17b, 4.8d 2.3E, LF17), using Surface Plasmon
Resonance assay (SPR), capture ELISA, and Far Western assay.
The mAb IgGCD4, which binds to the CD4-binding site,othermal calorimetric analysis (ITC). All titrations were performed in duplicate,
nts the raw data depicting an endothermic reaction, where heat is consumed after
sumed by each injection of Env into CD4. Panel B represents integrated areas per
the number of binding sites cannot be determined based on the values on X-axis.
a such as entropy (ΔS), enthalpy (ΔH), affinity of interaction (K), and calculated
ta for each binding site in Env for CD4 are presented.
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results obtained with CD4 (Fig. 7A). The broadly reactive mAb,
b12, whose epitope overlaps the CD4-binding site, efficiently
recognized subtype B ΔV2 trimer, however, had negligible
reactivity for subtype CΔV2 trimer in capture ELISA (Fig. 7B),
as well as in SPR (data not shown). To determine the relative
exposure of the V3 loop in the subtype C ΔV2 trimer compared
to subtype B ΔV2 trimer, mAbs 447D and 391-95d were used.
The mAb 391-95d recognized both subtype B and C ΔV2
trimers with similar efficiency, suggesting that the conforma-
tional epitope recognized by this mAb in V3 loop is well
exposed in these trimers (Fig. 7C). Similar observations were
made for the mAb 447D (data not shown). As expected, both
subtype B and CΔV2 trimers were not recognized by a V2 loop
specific antibody (Fig. 7D). In the absence of sCD4, both
subtype C and B ΔV2 trimers were recognized by mAbs
directed to CD4-inducible epitopes. Upon binding to sCD4,
both trimers underwent conformational changes as reflected by
an increase in binding of the CD4 inducible specific mAbs 17b,
4.8d, 2.3E, and LF17. A typical example of binding of these
trimers to mAb LF17 is presented in Fig. 8A. In general, the
magnitude of binding of these mAbs to subtype C ΔV2 trimers
was lower compared to subtype B ΔV2 trimer; however, the
ability of subtype C ΔV2 trimers to undergo conformational
changes in the presence of CD4 was similar to subtype B ΔV2
trimers (Fig. 8B). The structural integrity of the purified subtype
C ΔV2 trimer was further demonstrated by its ability to beFig. 7. Immunochemical characterization of purified subtype C ΔV2 trimer
(filled circle) and subtype BΔV2 trimer (open circle) using a panel of mAbs i.e.
IgGCD4 (A), IgG1b12 (B), 391-95d (C), and G34 (D).recognized by a broadly neutralizing mAb 2F5 (Fig. 8C).
Comparative affinity of binding of subtype B and C ΔV2
trimers to 2F5 is presented in Fig. 8D. The 2F5 mAb recognizes
a conserved neutralization epitope located in the ectodomain of
the gp41 subunit. In addition, sera from HIV-1 infected
individuals recognized both subtype B and C Env proteins,
suggesting that immunodominant epitopes (other than the ones
recognized by above-mentioned mAbs) are preserved and
exposed similarly on these trimers (data not shown). Based on
these observations, most of the critical neutralizing epitopes
were intact and preserved on subtype C trimers.
Biophysical characterization of o-gp140ΔV2TV1
The subtype C Env protein was analyzed using triple
detector analysis to estimate mass and hydrodynamic radius.
The light scattering profile and hydrodynamic radius for
subtype C Env are shown in Fig. 9A. The molecular mass of
subtype C trimer was calculated to be 450 kDa, and the
hydrodynamic radius was 10.7 nm. The light scattering profile
suggested that the purified Env protein was predominantly
homogeneous, with only a small proportion (b10–15%) in an
aggregated state. The mass of the aggregates was estimated to
be 868 kDa, nearly double the mass of trimer, suggesting that
the aggregated state consisted of at least two or more trimers.
Taken together, these data suggest that subtype C ΔV2 trimer
was larger than the subtype B ΔV2 trimer (SF162), and had an
increased ability to aggregate.
Negative stain EM
The biochemical data indicated that purified Env protein is
predominantly in a trimeric conformation (Fig. 3A). To further
assess quaternary structure, negative stain electron microscopy
analyses were carried out on different pools of Env protein. The
representative fields from pool 3 are shown in Fig. 10A. The
faster migrating molecules in pools 4 and 5 revealed images
consistent with both monomeric and dimeric forms (data not
shown), whereas molecules present in pool 3 appear to be
primarily composed of three-lobed (trimeric) configurations
(panel A and B). Unlike subtype BΔV2trimers expressed in the
same cells and purified the same way, it was quite remarkable to
observe that ΔV2 trimers derived from subtype C were in two
dominant conformations: (i) tight conformation with a smaller
diameter (panel C), and the other (ii) extended conformation
based on the position and size of the of the lobes (panel D). To
illustrate the differences in the conformation of these molecules,
we have also drawn side and top views of these molecules
(panels E and F). It is possible that the observed variations in the
conformational states of the molecule may also be due to
different projections of the three-dimensional molecular volume
of the trimer.
The dimensions of the subtype C Env molecules were in a
range of 55–60 Å for the monomer, and 90–130 Å for the trimer.
These data are consistent with previously reported measure-
ments of the SOS gp140JR-FL construct (Schulke et al., 2002).
The trimers appear from the top as a triangular arrangement with
a base of ∼130 Å and a depth of ∼90 Å. These dimensions are
consistent with the putative arrangement of gp120 in a trimeric
Fig. 8. Recognition of subtype B and CΔV2 trimers by different mAbs using SPR technique. The reactive surface was prepared by individually capturing different mAbs (2.3E, LF17, 1.12D, 17b, and 4.8D) on CM5Bia-
chip, and flowed purified subtype C and B Env trimers with (light shaded line) and without (dark shaded line) CD4. Data were analyzed using Biaevaluation 3.2 software. A typical example of binding of subtype B and C
ΔV2 trimers to mAbs LF17 in the presence and absence of CD4 is presented in panel A. Comparative up-regulation of CD4i epitope in subtype C (solid box) and B (open box)ΔV2 Env trimers upon binding to CD4 by a
panel ofmAbs recognizingCD-inducible epitopes is presented in panel B. Exposure of 2F5 epitope present in themembrane proximal region of subtype CΔV2 trimer is presented in panel C. Different concentrations (37 to
250 nM) of subtype C ΔV2 were flowed over 2F5 for kinetic analysis. Comparative affinity of subtype B and C ΔV2 trimers for 2F5 is presented in panel D.
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Fig. 9. Biophysical characterization of purified subtype C ΔV2 trimer using triple detector array system. Light scattering responses, and calculated hydrodynamic
radius are plotted with respect to time and presented in panel A. Majority of the purified protein is homogeneous as indicated by light scattering profile, and
hydrodynamic radius. A summary of biophysical properties of subtype C trimer is presented in panel B.
Fig. 10. Electronmicrographs of subtype CΔV2 trimer obtained from pool 3 (Fig. 4A) are presented in panel A. Selected trimers obtained from pool 3 showing different
conformation are presented in panel B. Representative sets of trimers potentially in tight and extended conformations are shown in panels C and D, respectively. To
illustrate the potential conformational differences between these molecules, we have drawn the molecules in tight and extended conformation in panels E and F,
respectively. The scale bar represents 50 nm.
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estimated from the STEM micrographs (data not shown)
indicated the presence of mono-disperse protein solutions, show-
ing well-behaved Gaussian distributions corresponding to a mass
of 113 kDa for the monomers and 353 kDa for the trimers (with-
out the water molecules). A larger mass distribution was ob-
served for the trimers (with a standard deviation of ∼8% of the
mean for the trimers versus ∼5% for the monomer), which may
be due to a smaller amount of aggregates or a lower proportion of
heterogeneity in the carbohydrate moieties in the trimers.
Discussion
The HIV Env glycoprotein is the target of broadly cross-
reactive nAbs and will be an important component of a
successful HIV vaccine. Therefore, it is important to engineer
the most relevant Env protein conformation for inclusion in a
potential HIV vaccine. It is well documented that gp120
monomer elicits high titer anti-env binding antibodies (Barnett
et al., 1997; Haigwood et al., 1992; Mascola et al., 1999; Steimer
and Haigwood, 1991) that neutralize T-cell adapted viruses, but
are limited in their ability to neutralize primary isolates (Mascola
et al., 1996; Moore et al., 1995; VanCott et al., 1995; Wrin and
Nunberg, 1994). Furthermore, the antibodies induced by gp120
react more strongly to monomer as compared to oligomer
(Broder et al., 1994; VanCott et al., 1995). The observation that
broadly reactive nAbs, such as IgG1b12, 2G12, and 2F5,
generally have stronger affinity for the native envelope (trimer)
than for monomeric gp120 or gp41 (Fouts et al., 1997; Roben
et al., 1994) provides, at least conceptually, the impetus to
evaluate trimeric Env glycoproteins as vaccine candidates
(Binley et al., 2000; Iyer et al., 2007; Pancera et al., 2005;
Quinnan et al., 2005; Sanders et al., 2000, 2002; Srivastava et al.,
2003, 2002; Yang et al., 2000a,b, 2002, 2001; Zhang et al.,
2007). So far, the data support this approach, as oligomers have
shown to be more effective in inducing strong antibody
responses to conformational epitopes (Earl et al., 1994; VanCott
et al., 1995; Yang et al., 2001). We have reported that a soluble
oligomeric gp140 immunogen derived from the envelope of
SF162 elicited cross-reactive nAbs in rabbits and macaques
(Barnett et al., 2001). In addition, we have demonstrated that the
animals immunized with o-gp140ΔV2 SF162 were partially
protected after pathogenic challenge with SHIVSF162P4(Barnett
et al., 2001). Finally, we have also shown that, in intranasal
prime and intramuscular boost regimen, subtype B trimeric Env-
based vaccine induced strong antibodies that neutralized heter-
ologous subtype B primary isolates (Srivastava et al., 2003;
Vajdy et al., 2004). In addition, Quinnan and colleagues induced
potent antibodies that neutralized diverse primary isolates using
an alpha prime and oligomeric protein boost strategy. Further-
more, immunized rhesus macaques were protected against the
partially pathogenic SHIVDH12R (Clone 7) as reflected by the
reduced magnitude and duration of viral load (Quinnan et al.,
2005). More recently, Zhang et al. compared the immunogenic-
ity of oligomeric and monomeric Env in rabbits. They have
clearly demonstrated that oligomeric Env is a better and more
potent immunogen compared to monomer. Rabbits immunizedwith oligomeric Env induced antibodies that achieved 50%
neutralization of 48/48, and 80% neutralization of 43/46 primary
strains of diverse HIV-1 subtypes tested. The strains tested
included members of standard panels of subtype B and C strains,
and other diverse strains known to be neutralization resistant.
However, the gp120R2 induced antibodies that neutralized 9/48
of the same strains (Zhang et al., 2007). These results
demonstrate that induction of truly broad spectrum nAbs is an
achievable goal in HIV-1 vaccine development. We have
recently extended these studies on trimeric Env to subtype C,
which is more prevalent in Sub-Saharan Africa and Asia. Based
on various biochemical, immunological, and physical criteria,
trimeric subtype C Env proteins were similar in most aspects to
subtype B Env. In proof of concept immunogenicity studies in
rabbits and monkeys, we have shown that ΔV2 trimers derived
from TV1 induced antibodies that neutralized some heterolo-
gous isolates (Lian et al., 2005) and hence hold promise as
vaccine candidates.
To elicit functional antibody responses, oligomeric HIV Env
immunogens need to be stabilized to retain their trimeric
conformation upon delivery. Several approaches are currently
being used: (1) elimination of the protease cleavage site
between gp120 and gp41 (Broder et al., 1994; Earl et al.,
1994, 1991, 2001); (2) introduction of intramolecular disulfide
bond formation (SOS) between gp120 and gp41 (Binley et al.,
2000; Farzan et al., 1998; Sanders et al., 2000; Schulke et al.,
2002); (3) in addition to the SOS modifications, introduction of
an isoleucine-to-proline substitution at position 559 in the N-
terminal heptad repeat region of gp41 (SOSIP) (Iyer et al., 2007;
Sanders et al., 2002); (4) extension of the gp41 coiled coil
region by the addition of GCN4 (a transcription factor that
normally forms stable homotrimers) sequences, either alone or
in conjunction with added cysteines between gp120 and gp41
(Farzan et al., 1998; Yang et al., 2000a,b); and (5) addition of a
trimerization domain from the C terminus of bacteriophage T4
fibritin (Yang et al., 2002). We have used the protease cleavage
site mutation strategy to create stable trimers from subtype B
(Srivastava et al., 2003, 2002), and now from subtype C.
Consistent with our previous work on SF162, we observed that
several mutations in the primary and secondary cleavage sites
are required for creating stable subtype C trimers. It appears that
sequence variation, glycosylation, size of variable loops,
expression levels, and the type of protein expression system
may all play roles in stabilizing the HIV Env glycoprotein in
oligomeric conformation (Yang et al., 2000a,b). Therefore,
optimal strategies for the generation of stable, soluble HIV
envelope oligomers from a given isolate or clade will need to be
determined experimentally on a case-by-case basis.
The binding of HIV Env protein to CD4, an obligatory step
in viral replication (Dalgleish et al., 1984; Klatzmann et al.,
1984), is dependent upon conformation (Lasky et al., 1987;
McDougal et al., 1986) and glycosylation (Barr et al., 1987; Li
et al., 1993; Papandreou et al., 1996). Evidence so far suggests
that N-linked glycosylation is important for the formation of
disulfide bonds which indirectly facilitate functional confor-
mation and binding to CD4 (Fennie and Lasky, 1989; Fenouillet
et al., 1989; Leonard et al., 1990; Li et al., 1993). The V2 loop
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position 186 (Ly and Stamatatos, 2000; Maezawa et al., 1983)
did not affect the ability of o-gp140ΔV2TV1 to bind to sCD4,
suggesting that the purified protein was in its correct native
conformation. The apparent affinity, kinetics, and thermody-
namics of the CD4-Env interaction were studied by SPR and
ITC. The dissociation constant (KD) for subtype C Env trimer
was in nanomolar range and not significantly different from the
KD of subtype B trimer (Sharma et al., 2006; Srivastava et al.,
2003). To determine if all three CD4 binding sites in a trimer are
accessible for CD4 binding, we performed ITC analysis.
Consistent with our previous data for subtype B (Sharma
et al., 2006), all three CD4 binding sites in subtype C trimer
were accessible to CD4. However, what is unique about subtype
C trimers is that the three CD4 binding sites have different
affinities, suggesting a co-cooperativity for CD4 binding. Using
gp120-GCN4 trimers, Pancera et al. (2005) have shown that
only two out of the three CD4 binding sites were accessible in
gp120 trimers, and the third binding site was exposed only upon
deletion of variable loops 1 and 2. It is possible that access to all
three binding sites may be dependent upon the orientation of the
monomers, which is controlled by gp41. It appears that the
folding of trimers created by a heterologous trimerization
domain such as GCN4 (Pancera et al., 2005) is different from
that of the trimers created by native gp41 sequence (Sharma
et al., 2006; Srivastava et al., 2003), as reflected by the acces-
sibility of the CD4 binding sites. Our data generated using SPR,
ITC, and mAb binding suggest that both subtype B and C Env
proteins underwent significant molecular rearrangement upon
binding to CD4. Similar findings were reported by Stites et al.
(1997). It is important to emphasize that thermodynamic param-
eters are highly dependent on the experimental conditions such
as pH, temperature, buffer, etc.; therefore it is generally difficult
to compare thermodynamic properties of similar molecules ob-
served from different studies. Nevertheless, apparent affinities
measured by SPR, as well as enthalpies and Gibbs free energies
calculated from ITC data for subtype B and C trimers, were
remarkably consistent with previous results. In those experi-
ments, gp120 derived from a different isolate was produced in
insect cells and was used under different experimental condi-
tions. Myszka et al. (2000) reported that full-length gp120
expressed in Drosophila bound to CD4 with an affinity of
22 nM and an apparent Gibbs free energy of −9.5 kcal/mol.
Similar data were obtained for subtype B V2 loop-deleted tri-
mers (Sharma et al., 2006), and also for subtype C trimers(data
not shown).
As mentioned previously, glycosylation of the Env is not
directly involved in CD4 binding; however, it provides a func-
tional conformation to facilitate CD4 binding. As a measure of
proper glycosylation, we demonstrated that the purified subtype
C Env trimers contained predominantly N-linked oligosacchar-
ides, similar to monomeric and trimeric derived from other
subtypes (Kozarsky et al., 1989; Srivastava et al., 2002). Fur-
thermore, we found that there are three kinds of polysaccharides
associated with Env. We purified and sequenced two poly-
saccharides, and found that they were of terminal mannose and
complex types. Similar observations were made of Env trimersderived from subtype B isolates such as US4 and SF162, and
consistent to what is reported for native and recombinant Env
proteins.
There is no consensus regarding the structure and the mass of
recombinant HIV Env glycoproteins. Differences in the
observed mass of putative trimers may be because they were
derived from different isolates, produced under different condi-
tions, and characterized by different techniques (Broder et al.,
1994; Earl et al., 1990, 1991; Grundner et al., 2002; Schulke
et al., 2002; Yang et al., 2000a, 2002). In the present study, we
performed an in-depth biophysical characterization of the
purified subtype C protein by using triple detector analysis and
negative stain EM. Combined, these methods strongly support
the conclusion that the purified Env protein was predominantly
in a trimeric conformation. As shown earlier, we found that the
monomeric Env proteins had higher Rh values of 5.07 nm for
gp120US4; and 4.33 nm for gp120SF162ΔV2 (Srivastava et al.,
2003, 2002). In contrast, Env glycoprotein trimers were tightly
folded structures, as indicated by smaller than expected Rh
values: 8.4 nm for o-gp140US4 and 7.6 nm for subtype B ΔV2
trimer (Srivastava et al., 2003, 2002), and 10.87 nm for subtype
C trimer. It is quite surprising to observe that cleaved subtype A
trimers produced using SOSIP approach have a size of 12–
13 nm which is very similar to what we observed for uncleaved
subtype C V2 loop-deleted trimers (Iyer et al., 2007). These data
are consistent with earlier observations that there are significant
differences in the structure and folding of monomer and trimer
(Moore et al., 1994; Wyatt et al., 1998). The reported molecular
mass for transiently expressed Env protein oligomers derived
from JR-FL, YU2, and HxBc2 is smaller than expected (400–
410 kDa) (Binley et al., 2000; Yang et al., 2000a), and the
molecular mass of the oligomer derived from JR-FL using
SOSIP approach is considerably larger than expected (Grundner
et al., 2002; Sanders et al., 2002). More recently, Jeffs et al.
(2004) have purified and characterized Env oligomers derived
from different primary isolates, and it was quite puzzling to note
that, with the exception of Env proteins derived from subtype F
and O, all the other Envs derived from other subtypes (A, B, C,
and D) were aggregated. Therefore, it is not trivial to purify Env
proteins in correct structure and conformation.
To further evaluate subtype C Env structure, we performed
deep-stain EM analysis and found the trimers to be in two basic
conformations, which were characterized as open and closed.
This is in contrast to our previous observations with subtype B
Env, which appeared to be in a single, closed conformation
(Srivastava et al., 2003). It is possible that a more relaxed or open
conformation, such as the one we observed for subtype C Env,
may provide more access thereby inducing a broader spectrum
of antibody responses.
We have determined the structural integrity of purified
subtype C trimer using several mAbs of known epitope speci-
ficity such as those near or on the CD4-binding site (recognized
by mAbs IgG1b12 and CD4-IgG2), the CD4-inducible site that
overlaps the co-receptor binding site (recognized by mAb 17b
and 4.8d, 2.3 E, LF17), gp41 (2F5), a carbohydrate-dependent
epitope on gp120 (recognized by 2G12), and V3 loop epitopes
(recognized by mAbs 447D and 391-95d). Interestingly,
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versus subtype B Env (Srivastava et al., 2003). Trimers derived
from subtypes B and C bound to CD4 and mAb IgG-CD4;
however, subtype C trimers showed no binding to b12 in capture
ELISA assay and had 20-fold reduced binding to b12 by
Biacore. Similarly, Jeffs et al. (2004) did not observe binding of
subtype C Env to b12. Is it because the epitope recognized by
b12 was not preserved on subtype C trimers, or because the b12
epitope is different on subtype C compared to subtype B? We
have aligned the amino acid residues involved in b12 binding
between subtype B and subtype C isolates, and observed that 5
out of 15 residues in subtype C are different compared to subtype
B. If the difference in b12 binding between subtype B and C
trimeric V2 Env can be attributed to this difference, remains to be
determined. It has been observed by David Montefiori (personal
communication) and Julie Overbaugh (personal communica-
tion) that the concentration of b12 required to neutralize TV1
virus is at least a log higher than that required for SF162 virus.
These data are consistent to the fact that b12 epitope is not
completely preserved in subtype C isolate compared to subtype
B. In general, the magnitude of binding of mAbs directed against
the CD4i epitopes was lower for subtype C trimer compared to
subtype B trimer either in the presence or absence of CD4.
However, the fold increase in the mAbs directed against CD4-
inducible epitopes observed in presence of CD4 was similar for
subtype B and C trimers, suggesting that subtype C trimer also
underwent structural rearrangement. The other broadly neutral-
izing epitopes such as those recognized by mAbs 2F5 and 4E10
were exposed and preserved in subtype C Env trimers. However,
these epitopes appear to have been lost or not preserved in Env
derived from another subtype C isolate BA29 (Jeffs et al., 2004).
Whether this was due to differences between the TV1 and BA29
strains or due to aggregation of the BA29 Env preparation re-
mains to be determined.
Taken together, the data demonstrate that a V2-deleted form of
Env trimer derived from theTV1 subtypeC strain can be produced
in – and purified from – CHO cells. The resulting preparation is
predominantly trimerwithmany similar biophysical, biochemical,
and immunological characteristics to subtype B Env protein.
Furthermore, it has induced nAb responses in rabbits, consistent
with our previously reported immunogenicity studies in rabbits
and rhesusmacaques (Lian et al., 2005). These data emphasize the
potential role of trimeric Envs for vaccine applications.
Materials and methods
Cloning full length or V2-modified subtype C HIV envelope
variants
The sequences encoding the open reading frame of the
ectodomain of the Env protein from the HIV-1 TV1ΔV2 isolates
were codon-modified as described elsewhere (Haas et al., 1996;
zur Megede et al., 2000), and constructed synthetically as a
2.1 kb EcoRI–XbaI DNA fragment. In order to stabilize the
oligomeric structure of the encoded gp140 protein, we in-
troduced a series of mutations in the primary (REKR) and sec-
ondary protease (KAKRR) cleavage sites in the Env polypeptide(Earl and Moss, 1993). The details of these mutations are
presented in Fig. 1. The synthetic PCR products were digested
with EcoRI/XhoI and cloned into the pCMVIII vector for protein
production. The pCMVIII vector contains the CMV immediate
early enhancer and promoter, a polylinker for multiple cloning
sites, a bovine growth hormone polyA termination signal, a
kanamycin resistance gene, and an E. coli origin of replication.
In addition, it contains Mdhfr (Dihydrofolate reductase) and
Neomycin resistance genes that allow for stable transfection,
selection and amplification of the gene of interest in Chinese
Hamster Ovary (CHO) cells. Similar methods were used to clone
a consensus envelope gene (E0975) derived from published
subtype C sequences from Botswana.
Transient transfection
Plasmids encoding the various gp140 forms of the TV1 env
were transiently transfected into 293T cells, and gp140 protein
expression was quantitated 48 to 72 hour post-transfection in cell
lysates and in supernatants. The supernatants were used for
partial purification of the Env protein from different clones.
These semi-purified subtype C Envs were screened for their
ability to bind CD4, and to determine levels of expression by
SDS-PAGE analysis and quantitative immunoprobing.
Development of stable CHO cell lines secreting o-gp140ΔV2TV1
Stable CHO cell lines secreting gp140ΔV2TV1were derived
using DG-44 cells that have a double deletion mutation in the
DHFR gene, thus making the cell line dependent on the addition
of hypoxanthine, glycine, and thymidine to the growth media,
following the experimental protocol described elsewhere
(Srivastava et al., 2002).
Production of o-gp140ΔV2TV1
The three highest expressing gp140ΔV2TV1-CHO cell
clones were used to seed 3 L bioreactors (one for each clone)
for adaptation to low serum containing media (0.5%) and cell
density and perfusion rate that facilitated the maximum
expression of gp140ΔV2TV1. Bioreactors were monitored
daily for cell density, pH, dCO2, dO2, glucose, lactate,
glutamine, and ammonia concentrations. The structure, confor-
mation, and expression levels of secreted gp140ΔV2TV1 were
monitored weekly. From the three bioreactor-adapted clones, the
best producer clone was used to seed a 12.5 L bioreactor for
production run. At the end of the run, collected media was
concentrated 20-fold through a 100-kDa-membrane filter and
stored at −80 °C in presence of 1 mM EDTA and 1 mM EGTA.
Purification of o-gp140ΔV2TV1
The o-gp140ΔV2TV1 was purified from the concentrated
CHO cell supernatant using a lectin capture, and two ion ex-
change steps as described elsewhere in detail (Srivastava et al.,
2003, 2002). All the column fractions were analyzed on poly-
acrylamide gels (PAGE; native, and reduced and denatured
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below). The fractions showing strong CD4 binding activity were
pooled and fractionated on a 16×90 mm Superdex-200column
(Pharmacia, Sweden) equilibrated with 10 mM NaCitrate
containing 300 mM NaCl. Fractions containing o-gp140ΔV2
were pooled, concentrated using a Stir cell (Millipore, Inc.,
Bedford, MA), and stored frozen at −80 °C. During the puri-
fication process, fractions were analyzed by PAGE both under
reducing and denaturing and under native conditions following
standard methods. Gels were stained with Coomassie brilliant
blue or processed for immunoblotting.
Biophysical characterization of o-gp140ΔV2TV1
The molecular mass (Mw), hydrodynamic radius (Rh), and
intrinsic viscosity (IV) of o-gp140ΔV2TV1 were determined
using a triple detector array system (TDA 300, Viscotek Corp.,
Houston, TX) in conjunction with a pre-calibrated gel filtration
HPLC column (Bio Sil SEC-250; BioRad Laboratories, Hercules,
CA) using Alliance 2690 HPLC system (Waters Corporation,
Milford, MA). Approximately 100 μg of the purified protein
(gp140ΔV2TV1) was analyzed in 20 mM NaH2PO4, 2 mM
Na2HPO4 buffer at pH7.4 at the flow rate of 1ml/min. The signals
from light scattering, viscometer, and refractive index detectors
were collected and analyzed using EZ Pro software package
(Viscotek Corp., Houston, TX).
CD4 binding assay
To determine the capability of purified envelope protein to bind
CD4, we used an HPLC-based assay using fluorescinated CD4 as
described elsewhere in detail (Srivastava et al., 2002). Purified
sCD4 was labeled with amine-reactive succinimidyl esters of
carboxyfluorescein following the instructions provided by manu-
facturer (Molecular Probes, Inc., Eugene, OR). Approximately
1μg of purifiedHIVEnv protein gp120wasmixedwith 0.33 μg of
fluorescinated-CD4 (equal molar concentrations) in a reaction
volume of 60 μl using 2× phosphate-buffered saline at pH 7.4.
After a 15 min incubation at the RT, 50 μl of this sample was
injected onto a Bio Sil SEC-250 (Bio-Rad laboratories, Hercules,
CA) gel filtration high performance liquid chromatography
(HPLC) column using Alliance 2690 HPLC system (Waters
Corporation, Milford, MA). Samples were run in 20 mM
NaH2PO4, 2 mM Na2HPO4,and 400 mM ammonium sulfate
buffer, pH6.0, at the flow rate of 1ml/min. The fluorescence profile
was monitored at 490 nm using a 996 fluorescent detector and
Millennium software package (Waters Corporation, Milford, MA).
Glycosylation profile analysis
The glycosylation profile of the purified proteins was
assessed by four methods as described elsewhere in detail
(Srivastava et al., 2002): first, enzymatic deglycosylation of the
purified HIV-Env proteins was performed using reagents from
BioRad Research Laboratories, Hercules, CA (catalog # 170-
6500). Briefly, to detect N-linked and O-linked oligosacchar-
ides, 25–100 μg of the purified protein was treated separatelywith Peptidyl N-glycosidase F (PNGF) (2.5 U/ml; at 37 °C for
1 h); and NANase II and O-glycosidase (1 U/ml; at 37 °C for
1 h). At the end of the incubation period, samples were diluted in
sample buffer containing 0.1% SDS and β-mercaptoethanol and
analyzed by SDS-PAGE. In addition, we have also performed
Endo-H digestion of the purified protein following manufac-
turer's protocol (Boehringer Mannheim).
Immunochemical characterization of o-gp140ΔV2TV1
The binding of well-characterized HIV-Env specific mAbs,
all derived from clade B HIV-1-infected patients, was performed
by a capture ELISA. Subtype C ΔV2 trimers were captured by
its gp41 portion via the mAb D50 that recognizes a linear gp41
peptide (Earl et al., 1997) as described previously (Stamatatos
and Cheng-Mayer, 1995). Briefly, ELISA plates were coated
with these respective antibodies at a concentration of 10 μg/ml
and o-gp140ΔV2 from subtypes B and C was captured. The
captured proteins were incubated with serial dilutions of various
mAbs (0.01 mg/ml to 10 mg/ml) for 2 hour at RT. Plates were
washed, and specifically bound antibodies were detected using
anti-mouse IgG coupled to alkaline phosphatase as described
earlier (Srivastava et al., 2003, 2002).
Surface plasmon resonance assay
Surface Plasmon Resonance assays were performed using a
BIACORE 3000 optical biosensor system (Biacore AB,Uppsala,
Sweden) with simultaneous monitoring of relevant flow cells. To
perform the kinetic study of the binding of subtype CΔV2 trimer
and subtype B ΔV2 trimer to sCD4, sCD4 was immobilized
using carbodiimide coupling onto a low charge CM3 sensor chip
to attain a response of 2000 RU. Using PBS (pH 7.4) with 0.05%
Tween 20, association was assessed by passing subtype C ΔV2
trimer and subtype B ΔV2 trimer over the CD4 in different flow
cells at a flow rate of 20–30 μl/min. The concentration range for
subtype C ΔV2 trimer and subtype B ΔV2 trimer was 15 to
500 mM. We have used Bovine Serum Albumin (BSA) as nega-
tive control. For kinetic analysis, Biosensor data were prepared
by subtracting binding responses obtained for BSA from the
specific responses. The association and dissociation phase data
were fitted simultaneously to a single-site binding model by
using the nonlinear data analysis software BIAevaluation 3.2.
mAbs binding assay
To perform the binding of HIV Env to different mAbs such as
b12, 2F5, 4E10, 2G12, 17b, 48d, 23E, and LF17, these antibodies
were immobilized on to CM5 sensor chip using amine coupling
reaction to attain approximately 1000 RUs, and the assay was
performed under the experimental conditions described as above.
Isothermal titration calorimetric (ITC) analysis
Isothermal titration calorimetry was performed on a VP-ITC
(Microcal LLC, Northampton, MA) using a 1.4 ml cell, and a
0.25 ml syringe. Proteins were dialyzed extensively in PBS
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(Millipore Inc.) prior to loading. Three to five millimolar CD4
was loaded in the cell, with 18 to 30 mM envelope protein in the
syringe. Titrations were performed using 15 μl injections with a
5 min delay between each injection. All runs were adjusted for
heat of dilution and mixing by subtracting a blank run of
envelope titrated into buffer only. Binding isotherms obtained
were auto-fitted for a floating number of binding sites using
Origin® software (MicroCal LLC, Northampton,MA). Fits were
generated using the Origin® 7.0 software parameter “ligand in
cell” option; thus, generated figures for the trimers do not reflect
the n values on the X-axis due to the software, which does not re-
calculate the molar ratio on the figure but does reflect the change
in the fit obtained (MicroCal LLC, Northampton, MA).
Immunoelectron microscopy
EM analysis of HIV Env derived from subtype C in different
conformations such as trimer, dimer, and monomer was
performed by negative staining as previously described
(Srivastava et al., 2003). The trimeric (pool 3; Fig. 4A), dimeric
(pool 4; Fig. 4A), and monomeric (pool 5; Fig. 4A) proteins
obtained after the final preparative sizing column were diluted in
borate-buffered saline, affixed to carbon membranes, stained
with 1% uranyl formate, and mounted on copper grids for
analysis. Electron micrographs were recorded at a nominal
magnification of 100,000× at 100 kVon a JEOL JEM 1200EX
electron microscope. Measurements were made using image
analysis software Image-Pro Plus (http://www.mediacy.com/).
Fifty or more particles from fractions corresponding to the
putative monomer/dimer and trimer of gp140ΔV2 TV1 were
measured and analyzed statistically.
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